Clinical Trials /

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer



The purpose of this study is to compare any good and bad effects of using ramucirumab along with the usual trastuzumab and chemotherapy to using the usual chemotherapy and trastuzumab alone.

Related Conditions:
  • Adenocarcinoma of the Gastroesophageal Junction
  • Gastric Adenocarcinoma
Recruiting Status:



Phase 2

Trial Eligibility



  • Brief Title: Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
  • Official Title: Phase II Study of Ramucirumab With Trastuzumab, Fluoropyrimidine, and Platinum in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer

Clinical Trial IDs

  • ORG STUDY ID: 15-301
  • NCT ID: NCT02726399


  • Gastric Cancer
  • Gastroesophageal Junction Cancer


RamucirumabRamucirumab With Trastuzumab and Capecitabine/Cisplatin
TrastuzumabRamucirumab With Trastuzumab and Capecitabine/Cisplatin
CapecitabineRamucirumab With Trastuzumab and Capecitabine/Cisplatin
CisplatinRamucirumab With Trastuzumab and Capecitabine/Cisplatin


The purpose of this study is to compare any good and bad effects of using ramucirumab along with the usual trastuzumab and chemotherapy to using the usual chemotherapy and trastuzumab alone.

Trial Arms

Ramucirumab With Trastuzumab and Capecitabine/CisplatinExperimentalThis will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
  • Ramucirumab
  • Trastuzumab
  • Capecitabine
  • Cisplatin

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have pathologically or cytologically MSKCC confirmed diagnosis of
             gastric or GEJ adenocarcinoma.

          -  Patients must have Stage IV gastric or GEJ adenocarcinoma with HER2 overexpression
             and/or amplification as determined by next generation sequencing assay,
             immunohistochemistry (IHC 3+) or fluorescent in situ hybridization (FISH+ is defined
             as HER2:CEP17 ratio ≥ 2.0). MSKCC confirmation of HER2 status is not mandatory prior
             to enrollment and treatment on study. For patients with outside HER2 testing, if
             sufficient tissue is available HER2 testing will be repeated at MSKCC for purpose of
             analysis and will not impact the patient's eligibility.

          -  Available archival tumor tissue should be submitted to MSKCC for IMPACT analysis, but
             will not be required prior to registration. Note: if tissue is depleted, patient will
             still be eligible after discussion with the PI.

          -  Patients must have disease that can be evaluated radiographically. This may be
             measurable disease or non-measurable disease per RECIST 1.1.

          -  Patients may have received no prior chemotherapy for Stage IV disease. Patients may
             have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if more than
             6 months have elapsed between the end of adjuvant therapy and registration.

          -  Age of 18 years or older.

          -  ECOG performance status 0-1.

          -  Peripheral neuropathy ≤ grade 1

          -  Patients who have adequate hepatic function as defined by a total bilirubin ≤1.5 times
             upper limit of institutional normal value (ULN) mg/dL (except patients with Gilbert's
             disease), and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 times
             ULN or ≤ 5.0 times the ULN in the setting of liver metastases.

          -  Patients who have adequate hematologic function, as evidenced by absolute neutrophil
             count (ANC) ≥1500/μL, hemoglobin ≥9 g/dL (5.58 mmol/L), and platelets ≥100,000/μL.

          -  Patients who have adequate renal function as defined by calculated creatinine
             clearance ≥60 mL/minute using the Cockcroft-Gaul formula or equivalent method.

          -  Patients whose urinary protein is ≤2+ on routine urinalysis (UA; if routine analysis
             is >2+, a 24-hour urine collection for protein must demonstrate <2g of protein in 24
             hours to allow participation in this protocol).

          -  The patient must have adequate coagulation function as defined by International
             Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds
             above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin
             must be switched to low molecular weight heparin and have achieved stable coagulation
             profile prior to first dose of protocol therapy.

          -  Patients, must be postmenopausal, surgically sterile, or using effective contraception
             (hormonal or barrier methods).

          -  Female patients of childbearing potential must have a negative serum pregnancy test
             within 7 days of study entry.

        Exclusion Criteria:

          -  Patients who have uncontrolled or poorly-controlled hypertension (>160 mmHg systolic
             or >100 mmHg diastolic for >4 weeks) despite standard medical management.

          -  Patients receiving any concurrent anticancer therapy or investigational agents with
             the intention of treating gastric/GEJ cancer. Previously received trastuzumab as part
             of a regimen in the metastatic setting with evidence of progression. 89Zr-trastuzumab
             use as imaging agent for 89Zr-trastuzumab PET permitted.

          -  Patients having:

               -  Cirrhosis at a level of Child-Pugh B (or worse) or

               -  Cirrhosis (any degree) and a history of hepatic encephalopathy or clinically
                  meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is
                  defined as ascites from cirrhosis requiring diuretics or paracentesis.

          -  Active or clinically significant cardiac disease including:

               -  Congestive heart failure - New York Heart Association (NYHA) > Class II.

               -  Active coronary artery disease.

               -  Left ventricular function <50%.

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or

               -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months
                  before randomization, or myocardial infarction within 6 months before

               -  Patients who have experienced any arterial thromboembolic events, including but
                  not limited to myocardial infarction, transient ischemic attack, cerebrovascular
                  accident, or unstable angina, within 6 months prior to enrollment.

               -  Patients who are receiving chronic antiplatelet therapy, including aspirin,
                  nonsteroidal anti-infalmmatory drugs (NSAIDs, inluding ibuprofen, naproxen, and
                  others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin
                  (maximum dose 325 mg/day is permitted.

          -  Evidence or history of bleeding diathesis or coagulopathy.

          -  Patients who have experienced any Grade 3-4 GI bleeding within 3 months prior to

          -  Unwillingness to give written informed consent, unwillingness to participate, or
             inability to comply with the protocol for the duration of the study.

          -  Patients with prior trastuzumab treatment.

          -  Patients with known active brain or central nervous system metastases, including
             leptomeningeal disease. Patients with treated and asymptomatic brain metastases may be
             eligible after discussion with PI.

          -  Patients who are pregnant or breast-feeding.

          -  Patients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days
             prior to enrollment.

          -  The patient has undergone major surgery within 28 days prior to first dose of protocol

          -  Patients may not have had major surgical procedure within 2 weeks of registration.

          -  Patients who have elective or planned major surgery to be performed during the course
             of the clinical trial.Minor surgery/subcutaneous venous access device placement within
             7 days prior to first dose of protocol therapy is permitted.

          -  Patients may not have had radiation within 28 days prior to first dose weeks of

          -  Patients may not have any other medical condition or reason, in that investigator's
             opinion, makes the patient unstable to participate in a clinical trial.
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression Free Survival
Time Frame:6 months
Safety Issue:
Description:as measured from the start of the ramucirumab and trastuzumab to the date of either documentation of disease progression on chemotherapy with trastuzumab and ramucirumab or death.


Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Terminated
Lead Sponsor:Memorial Sloan Kettering Cancer Center

Trial Keywords

  • Ramucirumab
  • Trastuzumab
  • Capecitabine
  • Cisplatin
  • HER2-Positive
  • 15-301

Last Updated

January 21, 2020